Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
the cytokines set and immune response indicators have been identified.
Why it matters
Levels of certain immune response indicators, including TNFa, IL-6, and IL-1b, predicted different three-year courses of amnestic mild cognitive impairment, including conversion to dementia. This is a prediction finding about immune markers, not a treatment or cure.
-
30/100
The early diagnosis of Alzheimer's disease (ADD) has gained new significance through the further discovery of blood biomarkers.
Why it matters
This review describes the added value of blood-based biomarkers for early diagnosis of Alzheimer's dementia, noting they are less expensive, less invasive and faster than amyloid PET or CSF examination. It concerns diagnosis only and reports nothing about treating, curing or preventing the disease.
-
Auditory hallucinations in older age could be the first symptom of AD and even occur before cognitive decline.
Why it matters
This case report describes a person whose first symptom of Alzheimer's disease was hearing voices, which appeared before any cognitive decline. As a single case report, it is preliminary and does not test any treatment, cure, or prevention.
-
Alzheimer disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia in the elderly.
Why it matters
This review summarizes cerebrospinal fluid biomarkers of amyloid and tau pathology used in the clinical and biological diagnosis of Alzheimer disease. It notes that better access to such testing in Russia would help assess the true prevalence of AD and select patients for targeted therapies using monoclonal antibodies against abnormal brain proteins.
-
Die Therapie wird in Abhängigkeit von der Größe der Veränderungen und dem Auftreten hierdurch bedingter Symptome gegebenenfalls unterbrochen.
Why it matters
This commentary supporting anti-amyloid antibodies notes that treatment may be interrupted depending on the size of changes and resulting symptoms, so at least 3 MRIs are required in the first year. In very rare individual cases fatal bleeds occurred, sometimes in specific treatment constellations.
-
La hipótesis amiloide, que propone la acumulación del péptido ?-amiloide (?A) en la sinapsis, es el factor clave de la patogénesis de la enfermedad de Alzheimer (EA) y esta ha sido la idea dominante en el campo de la investigación de la EA durante casi 30 años.
Why it matters
This review describes lecanemab as an antibody that binds soluble amyloid-beta aggregates and, in the phase III CLARITY AD trial of 1795 participants, slowed cognitive decline by 27 percent over 18 months. It summarizes existing trial evidence rather than presenting new findings on curing or preventing the disease.
-
The deep-learning network was capable of learning the task of delineating pathologic and normal findings within minutes on a standard PC and performing the classification task with 100% accuracy in less than 1 millisecond per case.
Why it matters
A deep-learning network was able to classify amyloid PET findings with 100% accuracy in under a millisecond per case after very fast training on a standard PC. The authors say this does not replace a trained professional but can filter out clear-cut cases and free up expert time, which could help nuclear medicine handle the expected workload in Alzheimer's diagnostics.
-
Black Ohioans are concerned about the rising prevalence of Alzheimer’s Disease, however social barriers that prevent equitable access to care, support and treatment is of overwhelming concern.
Why it matters
In a small survey of Black Ohioans, 82% knew someone diagnosed with Alzheimer's disease or related dementia, 87% were concerned about developing it, and 94% believed lack of access to resources explains higher diagnosis rates among Black Americans. Only 35% said they were very knowledgeable about dementia.
-
Our study unveils the complex interplay between area deprivation and language decline in AD patients.
Why it matters
Among people with and without Alzheimer's disease, living in a more deprived neighborhood was linked to worse performance on a picture-naming language task. This shows an association between neighborhood disadvantage and language ability but does not test any treatment or prevention.
-
It has been some time since the Journal of Nuclear Medicine and Technology has published an article on best practices in amyloid imaging.
Why it matters
This article reviews best practices in amyloid imaging in light of FDA approval of new antiamyloid therapies that decrease amyloid plaques and slow progression of mild cognitive impairment. It describes how amyloid PET or lumbar puncture can document amyloid plaques before treatment, but does not test any treatment, cure, or prevention itself.
-
These results support a functional hippocampal anterior‐posterior differentiation in memory processes and further stress the importance of integrating the dissociation of the hippocampus along its long‐axis concerning functional connectivity in memory processes and dementia.
Why it matters
In a small sample of 13 healthy young controls, 14 healthy senior controls and 15 patients with mild cognitive impairment due to Alzheimer's, the volume of the posterior hippocampus predicted spatial memory performance, while the anterior hippocampus did not. This supports the idea that different parts of the hippocampus have different roles in memory, which may be relevant to understanding memory loss in Alzheimer's, but it is a small early study and does not test any treatment.
-
Identifying patients at risk for developing mild cognitive impairment (MCI) and Alzheimer disease (AD) remains challenging in clinical practice, even as scientific understanding of dementia advances generally.
Why it matters
This paper notes that the treatment options for Alzheimer disease have expanded with the regulatory approval of aducanumab, a disease-modifying therapy, and may be shifting away from symptomatic treatments such as cholinesterase inhibitors and memantine. It also states that the role of biomarkers in Alzheimer disease is increasing.
-
The development of new therapies to treat Alzheimer's disease is a focus of global drug discovery.
Why it matters
This paper describes research into more potent symptomatic treatments, particularly for behavioral disturbances, and into drugs that intervene in the disease's pathophysiology with the aim of halting or at least slowing progression. It notes that the focus of identifying people with Alzheimer's disease is shifting to pre-dementia stages such as Mild Cognitive Impairment or even asymptomatic stages.
-
We don’t understand Alzheimer, its origin and disease mechanisms.
Why it matters
This paper argues that the lack of disease-modifying Alzheimer's treatments today is due to the amyloid hypothesis, which has dominated research, drug development and trials for 30 years. It notes the hypothesis is not dead yet, as shown by the recent resurrection of clinical trials with aducanumab.
-
Preliminary results indicate 29 residential care facilities applied for evaluation in 2019.
Why it matters
This report describes a plan to activate 574 new Alzheimer's special care unit beds in the Metropolitan City of Milan to reach a target of 2 beds per 1000 people aged 65 and older. Preliminary results show that 29 residential care facilities applied for evaluation in 2019.
-
The present study was undertaken to validate the measurement of biomarkers as a supplement to the latest diagnostic criteria for Alzheimer disease (AD) dementia by National Institute on Aging-Alzheimer's Association (NIA-AA) work group using a sample attending a tertiary care center in Southern India.
Why it matters
In 20 patients in Southern India, this study measured cerebrospinal fluid amyloid, total tau and phosphorylated tau to support the NIA-AA diagnostic criteria for Alzheimer's dementia. It is about supporting diagnosis with biomarkers, not about treating, curing or preventing the disease.
-
Some studies have shown that CSF amyloid-beta 1-42 (Aβ₁₋₄₂), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau(181p)) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alzheimeŕs disease (AD).
Why it matters
In this small study of 36 patients with mild cognitive impairment, those with reduced cerebrospinal fluid amyloid-beta 1-42 progressed rapidly to Alzheimer's disease one year after lumbar puncture. This is prognostic information from a small sample and does not report any treatment, cure, or prevention.
-
The development of diagnostic markers for earlier and more reliable diagnosis of Alzheimer disease (AD) is essential, particularly because therapeutic medication is available for AD.
Why it matters
This paper discusses cerebrospinal fluid markers, including total tau and oxidized proteins, for distinguishing Alzheimer's disease from other conditions. It concerns diagnosis and does not report any treatment, cure, or prevention.
-
A blind study was set up to examine the in vitro growth characteristics of skin fibroblasts from 2 individuals with and 9 at risk for familial Alzheimer disease, 4 individuals with sporadic Alzheimer disease, 18 with Down syndrome as well as 5 younger and 6 older controls.
Why it matters
Skin fibroblast growth properties did not differ from age-matched controls in people with sporadic Alzheimer disease or Down syndrome, and only a modest difference was seen in a few familial Alzheimer disease cases that the authors say needs confirmation. The authors conclude these growth properties are not a good marker for any form of Alzheimer disease.
-
Introducción: La neuroinflamación ha adquirido creciente relevancia en la fisiopatología de la enfermedad de Alzheimer por su interacción con la acumulación de β-amiloide, la patología tau, la disfunción sináptica y la neurodegeneración. Microglía, astrocitos y múltiples vías de señalización inmunitaria constituyen potenciales dianas terapéuticas.
Why it matters
This systematic review examines neuroinflammation as a therapeutic target in Alzheimer's disease, covering microglia, astrocytes, inflammatory pathways, and strategies such as microglial modulation and immunotherapy. It concludes that direct clinical evidence remains limited by biological heterogeneity, lack of standardized biomarkers, late intervention, and limited translation, so no treatment is established.
-
controversias de los tratamientos de la enfermedad de Alzheimer» In response to 'Advances and controversies in the treatments of Alzheimer's disease' Sr. Editor, Felicitamos a la Dra.M.
Why it matters
This letter states there is no solid clinical demonstration that anti-amyloid antibodies change the progression of Alzheimer's disease, citing a Cochrane review finding little or no difference in dementia severity after 18 months. It also raises safety concerns, noting a marked increase in ARIA, with 119 of every 1,000 patients developing brain inflammation (ARIA-E) versus 12 per 1,000 on placebo, plus more microhemorrhages (ARIA-H).
-
Alzheimer Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β deposition, tau pathology, synaptic dysfunction, neuronal injury and cerebral atrophy.
Why it matters
This review describes how amyloid PET establishes amyloid pathology, tau PET relates to disease stage and severity, and FDG PET identifies neurodegeneration patterns. It covers diagnostic and prognostic uses of PET, including treatment selection, but does not itself test any treatment, cure, or prevention.
-
The predALZ framework achieved 94% accuracy on an independent test set and approximately 96% accuracy in cross-validation for Alzheimer-related driver gene prediction.
Why it matters
This study describes a machine learning framework that achieved high accuracy in predicting Alzheimer-related driver genes. This is a computational tool for research and does not directly provide a treatment, cure, or prevention for Alzheimer's disease.
-
ADAM10 plays a fundamental role in brain function, and sufficient studies support its involvement in AD pathogenesis.
Why it matters
This review reports that ADAM10 is involved in Alzheimer disease pathogenesis, though only isolated examples of ADAM10 mutations as a genetic cause exist. It states that enhancing ADAM10 expression remains a therapeutic target that requires further research, and that ADAM10 levels in platelets could be considered a biomarker.
-
The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head-to-head comparative data are absent.
Why it matters
This perspective addresses how clinicians should respond when patients ask which anti-amyloid immunotherapy the clinician would choose, given that head-to-head comparative data are absent. It offers a framework for balancing evidence-based medicine with the therapeutic alliance, but provides no data on treating, curing or preventing Alzheimer's disease.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Altered amyloid protein processing in platelets of patients with Alzheimer disease
- Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease
- Use of Immersive Virtual Reality in the Assessment and Treatment of Alzheimer's Disease: A Systematic Review
- Neurodegenerative Diseases Target Large-Scale Human Brain Networks
- A systematic literature review of automatic Alzheimer's disease detection from speech and language
- Trazodone improves sleep parameters in Alzheimer disease patients: a randomized, double-blind, and placebo-controlled study
- Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease
- Neuropathologic changes in Alzheimer's disease
- One night of closed-loop auditory stimulation during sleep enhances memory consolidation in patients with Alzheimer's Disease
- Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease